A Five-membered Cyclo Of The Polycyclo Ring System Consists Of Four Ring Carbons And One Ring Oxygen (e.g., Fused Rifamycins, Etc.) Patents (Class 540/457)
  • Patent number: 10282788
    Abstract: Methods and systems for processing insurance policies associated with properties may be provided. A home may be populated with smart devices that are connected to, or in communication with, a central (or “smart home”) controller, such as via wired or wireless communication. The smart devices are covered by an insurance policy, such as homeowners, renters, or personal articles insurance. The central controller may receive, with customer permission, service log information for the devices, and update an inventory list to include the service log information. The controller may detect that a smart device has been repaired, and then generate and transmit a notification to the customer. In some cases, the notification may prompt the customer to schedule a future repair event. The smart devices may be associated with appliances, electronics, computers, televisions, jewelry, vehicles, furniture, or other personal belongings. Insurance discounts may be provided based upon the service log/maintenance functionality.
    Type: Grant
    Filed: October 2, 2015
    Date of Patent: May 7, 2019
    Assignee: State Farm Mutual Automobile Insurance Company
    Inventors: Jackie O. Jordan, II, John Donovan, David Turrentine, Torri Wollenschlager, Bryan R. Nussbaum, Deanna Stockweather, Jeffrey W. Stoiber, Kerstin Markwardt, Gail L. Carlson, Kyle C. Schiebel, Troy Winslow, Joseph P. Harr, Ellakate Wagner, Michael Harris, Jr., Jennylind Sun
  • Patent number: 9452157
    Abstract: The present invention relates to rifaximin compositions comprising amino acids, characterized in that they increase rifaximin solubility in aqueous solutions and are useful in the treatment of disease wherein amino acids and rifaximin are efficacious. The present invention also relates to pharmaceutical compositions comprising rifaximin or one of the pharmaceutically acceptable salts thereof and one or more amino acid(s), wherein the molar ratio between the amino acid(s) and rifaximin is from 1:1 to 10:1, together with pharmaceutically acceptable excipients. The present invention further relates to rifaximin crystals obtained by dissolving rifaximin and amino acids in solutions formed by ethanol/water and evaporating the solution.
    Type: Grant
    Filed: July 3, 2013
    Date of Patent: September 27, 2016
    Assignee: Alfa Wassermann S.P.A
    Inventors: Giuseppe Claudio Viscomi, Laura Chelazzi, Fabrizia Grepioni, Dario Braga, Maddalena Kindt
  • Patent number: 9242917
    Abstract: The present invention relates to different forms of a HCV inhibitory compound.
    Type: Grant
    Filed: August 16, 2012
    Date of Patent: January 26, 2016
    Assignees: Merck Sharp & Dohme Limited, Merck Sharp & Dohme Corp.
    Inventors: Gregory L Beutner, Robert M Wenslow, Jr., Eric J Choi, Clinton Scott Shultz, Jeremy Scott, Juan D Arredondo, Laura Artino
  • Patent number: 9012441
    Abstract: Compounds of formula I: or salts thereof are disclosed. Also disclosed are pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula I, intermediates useful for preparing compounds of formula I and therapeutic methods for treating a Retroviridae viral infection including an infection caused by the HIV virus.
    Type: Grant
    Filed: January 9, 2014
    Date of Patent: April 21, 2015
    Assignee: Gilead Sciences, Inc.
    Inventors: Steven S. Bondy, Carina E. Cannizzaro, Chien-Hung Chou, Yunfeng Eric Hu, John O. Link, Qi Liu, Scott D. Schroeder, Winston C. Tse, Jennifer R. Zhang
  • Publication number: 20150045382
    Abstract: There is provided a complex comprising rifaximin and a complexing agent, wherein the complexing agent is a polyvinyl pyrrolidone (PVP) or a cyclodextrin. There is also provided a process for preparing the complex, a pharmaceutical composition including the complex and therapeutic uses of the complex.
    Type: Application
    Filed: October 22, 2014
    Publication date: February 12, 2015
    Inventors: Maruti Ganpati Ghagare, Sunilkumar Parasnath Saroj, Dharmaraj Ramachandra Rao, Rajendra Narayanrao Kankan
  • Publication number: 20150011750
    Abstract: A process is described which enables Rifaximin in a completely amorphous form to be obtained. Said process comprises the steps of dissolving crude Rifaximin in absolute ethanol while hot and then collecting after precipitation by—cooling the title compound under amorphous form.
    Type: Application
    Filed: April 24, 2014
    Publication date: January 8, 2015
    Inventors: Emilio Vecchio, Roberta Pizzocaro
  • Publication number: 20140378495
    Abstract: 25-desacetyl rifaximin or a pharmaceutically acceptable salt thereof is provided. Methods of treatment of bowl related disorders using isolated and/or purified 25-desacetyl rifaximin or a pharmaceutically acceptable salt thereof are also provided.
    Type: Application
    Filed: June 30, 2014
    Publication date: December 25, 2014
    Inventors: Pam Golden, Mohammed A. Kabir, Giuseppe Claudio Viscomi, Manuela Campana, Donatella Confortini, Miriam Barbanti
  • Publication number: 20140356376
    Abstract: The invention provides anti-wall teichoic acid antibodies and antibiotic conjugates thereof, and methods of using the same.
    Type: Application
    Filed: May 30, 2014
    Publication date: December 4, 2014
    Applicant: GENENTECH, INC.
    Inventors: Eric J. Brown, Martine Darwish, John Flygare, Wouter Hazenbos, Byoung Chul Lee, Sophie M. Lehar, Sanjeev Mariathasan, John Hiroshi Morisaki, Thomas H. Pillow, Leanna Staben, Richard Vandlen, Klaus Koefoed, Magnus Strandh, Peter S. Andersen
  • Publication number: 20140356375
    Abstract: The invention provides anti-wall teichoic acid antibodies and antibiotic conjugates thereof, and methods of using the same.
    Type: Application
    Filed: May 22, 2014
    Publication date: December 4, 2014
    Applicant: GENENTECH, INC.
    Inventors: Eric J. Brown, Martine Darwish, John Flygare, Wouter Hazenbos, Byoung Chul Lee, Sophie M. Lehar, Sanjeev Mariathasan, John Hiroshi Morisaki, Thomas H. Pillow, Leanna Staben, Richard Vandlen, Klaus Koefoed, Magnus Strandh, Peter S. Andersen
  • Patent number: 8883795
    Abstract: Provided for in the instant application are two additional polymorphic forms of rifaximin; namely substantially pure APO-I and APO-II. Also provided are processes for preparing substantially pure APO-I and APO-II. Rifaximin is a non-aminoglycoside antibiotic that has previously been found to be useful for the treatment of traveller's diarrhea caused by Escherichia coli bacteria, as well as in the treatment of irritable bowel syndrome, diverticular disease, hepatic encephalopathy, pyogenic skin infections and as an antibacterial prophylactic prior to colon surgery.
    Type: Grant
    Filed: June 16, 2011
    Date of Patent: November 11, 2014
    Assignee: Apotex Pharmachem Inc.
    Inventors: Kiran Kumar Kothakonda, Allan W. Rey
  • Patent number: 8877770
    Abstract: The present invention relates to a new polymorph of Rifaximin, designated ?, and to a process for the preparation thereof. Under certain aspects, the invention also relates to pharmaceutical compositions comprising an effective amount of the polymorphic form ? of Rifaximin and a pharmaceutically acceptable carrier and its uses in the treatment of gastrointestinal conditions.
    Type: Grant
    Filed: May 18, 2012
    Date of Patent: November 4, 2014
    Assignee: Clarochem Ireland Limited
    Inventors: Enrico Vigano', Renato Molteni, Simona Lanfranconi, Massimiliano Arrighi, Fabio Gatti
  • Patent number: 8871753
    Abstract: The present invention relates to macrocyclic compounds of Formula I: or pharmaceutically acceptable salts thereof or quaternary ammonium salts thereof wherein constituent members are provided hereinwith, as well as their compositions and methods of use, which are JAK/ALK inhibitors useful in the treatment of JAK/ALK-associated diseases including, for example, inflammatory and autoimmune disorders, as well as cancer.
    Type: Grant
    Filed: April 23, 2009
    Date of Patent: October 28, 2014
    Assignee: Incyte Corporation
    Inventors: Andrew Paul Combs, Richard B. Sparks, Eddy W. Yue, Hao Feng, Michael Jason Bower, Wenyu Zhu
  • Patent number: 8846734
    Abstract: Diazonamide analogs having anti-mitotic activity, useful for the treatment of cancer and other proliferative disorders, and related pharmaceutical compositions are provided.
    Type: Grant
    Filed: November 25, 2013
    Date of Patent: September 30, 2014
    Assignee: Joyant Pharmaceuticals, Inc.
    Inventors: Qi Wei, Ming Zhou, Xiaoming Xu, Charles Caldwell, Susan Harran, Lai Wang
  • Publication number: 20140235662
    Abstract: The present invention describes rifaximin powder and to a process for preparing the same. The invention relates also to a pharmaceutical composition in solid form comprising said rifaximin, pharmaceutically acceptable excipients and optionally other ingredients. The compositions according to the invention are suitable for oral administration and are characterized by producing a controlled release of rifaximin, whereby a long-lasting effect is obtained in a patient.
    Type: Application
    Filed: April 24, 2014
    Publication date: August 21, 2014
    Applicant: ALFA WASSERMANN S.P.A.
    Inventors: Giuseppe Claudio VISCOMI, Paola MAFFEI, Vittoria LAURO, Miriam BARBANTI, Donatella CONFORTINI, Dario BRAGA
  • Publication number: 20140200343
    Abstract: The present invention includes compounds useful as intermediates in the preparation of macrolactams, methods for preparing the intermediates, and methods for preparing macrolactams from the intermediates. One use of the methods and intermediates described herein is in the production of macrolactam compounds able to inhibit HCV NS3 protease activity. HCV NS3 inhibitory compounds have therapeutic and research applications.
    Type: Application
    Filed: August 16, 2012
    Publication date: July 17, 2014
    Inventors: Feng Xu, Guy Humphrey, Tao Pei, Zhiguo Jake Song, Tao Wang, Laura Artino
  • Publication number: 20140179916
    Abstract: The present invention relates to Rifaximin polymorphic forms, to their use in medicinal preparations and to therapeutic methods using them.
    Type: Application
    Filed: October 24, 2013
    Publication date: June 26, 2014
    Inventors: Karen S. Gushurst, Donglai Yang, Petinka Vlahova, Jeffrey S. Stults
  • Publication number: 20140155422
    Abstract: Process for the preparation of rifaximin, pseudo-crystalline rifaximin and a new pseudo-crystalline form of rifaximin with fewer impurities obtained thereby.
    Type: Application
    Filed: May 21, 2012
    Publication date: June 5, 2014
    Applicant: FRIULCHEM SPA
    Inventors: Disma Mazzola, Silvia Moiana, Germano Coppi
  • Publication number: 20140141081
    Abstract: The present invention relates to Rifaximin polymorphic, salt, hydrate, and amorphous forms, to their use in medicinal preparations and to therapeutic methods using them.
    Type: Application
    Filed: June 27, 2013
    Publication date: May 22, 2014
    Inventors: Karen S. Gushurst, Donglai Yang, Petinka Vlahova, Jeffrey S. Stults
  • Publication number: 20140128419
    Abstract: Amorphous rifaximin, methods of making it, and pharmaceutical compositions containing it. Also described are methods of converting amorphous rifaximin to crystalline rifaximin and vice versa.
    Type: Application
    Filed: January 10, 2014
    Publication date: May 8, 2014
    Applicant: CIPLA LIMITED
    Inventors: Dharmaraj Ramachandra Rao, Rajendra Narayanrao Kankan, Manjinder Singh Phull
  • Patent number: 8716293
    Abstract: Compound having formula I and pharmaceutically acceptable salts or solvates thereof, their pharmaceutical formulations and use as HIV inhibitors.
    Type: Grant
    Filed: April 1, 2011
    Date of Patent: May 6, 2014
    Assignee: Janssen R&D Ireland
    Inventors: Johannes Wilhelmus J. Thuring, Jean-Francois Bonfanti
  • Publication number: 20140107144
    Abstract: The present invention relates to a new polymorph of Rifaximin, designated ?, and to a process for the preparation thereof. Under certain aspects, the invention also relates to pharmaceutical compositions comprising an effective amount of the polymorphic form ? of Rifaximin and a pharmaceutically acceptable carrier and its uses in the treatment of gastrointestinal conditions.
    Type: Application
    Filed: May 18, 2012
    Publication date: April 17, 2014
    Applicant: CLAROCHEM IRELAND LIMITED
    Inventors: Enrico Vigano, Renato Molteni, Simona Lanfranconi, Massimiliano Arrighi, Fabio Gatti
  • Publication number: 20140100193
    Abstract: Diazonamide analogs having anti-mitotic activity, useful for the treatment of cancer and other proliferative disorders, and related pharmaceutical compositions are provided.
    Type: Application
    Filed: November 25, 2013
    Publication date: April 10, 2014
    Applicant: Joyant Pharmaceuticals, Inc.
    Inventors: Qi Wei, Ming Zhou, Xiaoming Xu, Charles Caldwell, Susan Harran, Lai Wang
  • Publication number: 20140079783
    Abstract: The present invention relates to rifaximin compositions comprising amino acids, characterized in that they increase rifaximin solubility in aqueous solutions and are useful in the treatment of disease wherein amino acids and rifaximin are efficacious. The present invention also relates to pharmaceutical compositions comprising rifaximin or one of the pharmaceutically acceptable salts thereof and one or more amino acid(s), wherein the molar ratio between the amino acid(s) and rifaximin is from 1:1 to 10:1, together with pharmaceutically acceptable excipients. The present invention further relates to rifaximin crystals obtained by dissolving rifaximin and amino acids in solutions formed by ethanol/water and evaporating the solution.
    Type: Application
    Filed: July 3, 2013
    Publication date: March 20, 2014
    Inventors: Giuseppe Claudio Viscomi, Laura Chelazzi, Fabrizia Grepioni, Dario Braga, Maddalena Kindt
  • Publication number: 20140011828
    Abstract: The present invention relates to Rifaximin amorphous forms, to their use in medicinal preparations and to therapeutic methods using them.
    Type: Application
    Filed: October 3, 2012
    Publication date: January 9, 2014
    Inventors: Karen S. Gushurst, Donglai Yang, Melanie Janelle Bevill, Nathan Carl Schultheiss, Giuseppe Claudio Viscomi
  • Publication number: 20130338355
    Abstract: A process is described which enables Rifaximin in a completely amorphous form to be obtained. Said process comprises the steps of dissolving crude Rifaximin in absolute ethanol while hot and then collecting after precipitation by—cooling the title compound under amorphous form.
    Type: Application
    Filed: August 19, 2013
    Publication date: December 19, 2013
    Inventors: Emilio VECCHIO, Roberta PIZZOCARO
  • Patent number: 8592469
    Abstract: Diazonamide analogs having anti-mitotic activity, useful for the treatment of cancer and other proliferative disorders, and related pharmaceutical compositions are provided.
    Type: Grant
    Filed: April 15, 2012
    Date of Patent: November 26, 2013
    Assignee: Joyant Pharmaceuticals, Inc.
    Inventors: Qi Wei, Ming Zhou, Xiaoming Xu, Charles Caldwell, Susan Harran, Lai Wang
  • Publication number: 20130310410
    Abstract: Crystalline polymorphous forms of the rifaximin (INN) antibiotic named rifaximin ? and rifaximin ? useful in the production of medicinal preparations containing rifaximin for oral and topical use and obtained by means of a crystallization process carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a determinate temperature and for a determinate period of time, followed by a drying carried out under controlled conditions until reaching a settled water content in the end product, are the object of the invention.
    Type: Application
    Filed: July 25, 2013
    Publication date: November 21, 2013
    Applicant: Alfa Wassermann, S.P.A.
    Inventors: Giuseppe Claudio Viscomi, Manuela Campana, Donatella Confortini, Maria Miriam Barbanti, Dario Braga
  • Publication number: 20130310409
    Abstract: Embodiments relate to Rifaximin polymorphic, salt, and hydrate forms, methods of producing polymorphic forms and to their use in medicinal preparations and to therapeutic methods using them.
    Type: Application
    Filed: July 24, 2013
    Publication date: November 21, 2013
    Inventors: Stephan D. Parent, Lisa Lynn McQueen, Patricia Andres, Paul Schields, Yiduo Wu, Fei Ding, Jared Peters Smit
  • Publication number: 20130289269
    Abstract: Crystalline polymorphous forms of rifaximin (INN), referred to as rifaximin ? and rifaximin ?, and a poorly crystalline form referred to as rifaximin ?, useful in the production of medicaments containing rifaximin for oral and topical use and obtained by means of a crystallization process carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a fixed temperature and for a fixed period of time, followed by a drying under controlled conditions until reaching a precise water content in the end product, are the object of the invention.
    Type: Application
    Filed: November 16, 2012
    Publication date: October 31, 2013
    Applicant: ALFA WASSERMANN, S.P.A.
    Inventor: ALFA WASSERMANN, S.P.A.
  • Publication number: 20130230498
    Abstract: The present invention provides for microbial compositions and methods for reducing the concentration of short-chain fatty acids in the gut as a way to reduce energy uptake and manage obesity. More specifically, the invention provides for decreasing short-chain fatty acids available for absorption in the human gut, such as acetate, using one or more of: a probiotic including a homo-acetogenic, acetate oxidizing bacterium that converts acetate to H2; a probiotic including an acetoclastic methanogen; a microbial electrolysis cell comprising a homo-acetogenic bacterium and/or an acetoclastic methanogen; a prebiotic that enhances the growth or function of acetate-scavenging microbiota; or a highly selective antibiotic that targets H2-oxidizing methanogens.
    Type: Application
    Filed: February 16, 2011
    Publication date: September 5, 2013
    Applicant: ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY
    Inventors: Bruce Rittmann, Rosa Krajmalnik-Brown, Husen Zhang, John Dibaise, Michael Crowell
  • Patent number: 8524691
    Abstract: The present invention relates to phosphonated Rifamycins, and methods of making and using such compounds. These compounds are useful as antibiotics for prophylaxis and/or the treatment of bone and joint infections, especially for the prophylaxis and/or treatment of osteomyelitis.
    Type: Grant
    Filed: August 10, 2009
    Date of Patent: September 3, 2013
    Assignee: The Medicines Company
    Inventors: Evelyne Dietrich, Ranga Reddy, Kelly Tanaka, Ting Kang, Yanick LaFontaine, Adel Rafai Far
  • Publication number: 20130090348
    Abstract: Provided for in the instant application are two additional polymorphic forms of rifaximin; namely substantially pure APO-I and APO-II. Also provided are processes for preparing substantially pure APO-I and APO-II. Rifaximin is a non-aminoglycoside antibiotic that has previously been found to be useful for the treatment of traveller's diarrhea caused by Escherichia coli bacteria, as well as in the treatment of irritable bowel syndrome, diverticular disease, hepatic encephalopathy, pyogenic skin infections and as an antibacterial prophylactic prior to colon surgery.
    Type: Application
    Filed: June 16, 2011
    Publication date: April 11, 2013
    Applicant: APOTEX PHARMACHEM INC.
    Inventors: Kiran Kumar Kothakonda, Allan W. Rey
  • Patent number: 8404664
    Abstract: The present invention relates to phosphonated Rifamycins, and methods of making and using such compounds. These compounds are useful as antibiotics for prophylaxis and/or the treatment of bone and joint infections, especially for the prophylaxis and/or treatment of osteomyelitis.
    Type: Grant
    Filed: August 11, 2006
    Date of Patent: March 26, 2013
    Assignee: Targanta Therapeutics, Inc.
    Inventors: Yannick Stephane Rose, Stephane Ciblat, Ting Kang, Adel Rafai Far, Evelyne Dietrich, Yanick Lafontaine, Ranga Reddy
  • Publication number: 20130072676
    Abstract: Polyols stabilize polymorphous form of rifaximin, in particular the ? form. When polyols having at least two hydroxy groups are added to rifaximin powder, polymorph ? is stable and remains stable in time independently from the environment humidity. In this invention a method to prepare formulations constituted by pure and stable polymorphous forms able to give a pharmaceutical product is described.
    Type: Application
    Filed: July 9, 2012
    Publication date: March 21, 2013
    Applicant: ALFA WASSERMANN, S.P.A.
    Inventors: Paola MAFFEI, Milena BACHETTI, Giuseppe BOTTONI, Giuseppe Claudio VISCOMI
  • Patent number: 8399452
    Abstract: This invention relates to compounds for the inhibition of histone deacetylase. More particularly, the invention provides for compounds of formula (I) wherein Q, J, L and Z are as defined in the specification.
    Type: Grant
    Filed: October 26, 2007
    Date of Patent: March 19, 2013
    Assignees: Methylgene Inc., EnVivo Pharmaceuticals
    Inventors: Robert Déziel, Silvana Leit, Patrick Beaulieu, Yves Andre Chantigny, John Mancuso, Pierre Tessier, Gideon Shapiro, Richard Chesworth, David Smil
  • Publication number: 20130004576
    Abstract: The present invention describes rifaximin powder and to a process for preparing the same. The invention relates also to a pharmaceutical composition in solid form comprising said rifaximin, pharmaceutically acceptable excipients and optionally other ingredients. The compositions according to the invention are suitable for oral administration and are characterized by producing a controlled release of rifaximin, whereby a long-lasting effect is obtained in a patient.
    Type: Application
    Filed: March 4, 2011
    Publication date: January 3, 2013
    Applicant: ALFA WASSERMANN S.P.A.
    Inventors: Giuseppe Claudio Viscomi, Paola Maffei, Vittoria Lauro, Miriam Barbanti, Donatella Confortini, Dario Braga
  • Patent number: 8338422
    Abstract: The present invention relates to compounds or pharmaceutically-acceptable salts thereof, processes for preparing them, pharmaceutical compositions containing them and their use in therapy. The invention particularly relates to certain indolin-2-ones and aza-indolin-2-ones which possess anti-tumor activity and are accordingly useful in methods of treatment of the human or animal body, in particular such compounds are useful in the treatment of pathological processes which involve an aberrant cellular proliferation, such as tumor growth, rheumatoid arthritis, restenosis and atherosclerosis.
    Type: Grant
    Filed: June 20, 2008
    Date of Patent: December 25, 2012
    Assignee: Janssen Pharmaceutica NV
    Inventors: Gaston Stanislas Marcella Diels, Marc Gustaaf Celine Verdonck, Peter Jacobus Johannes Antonius Buijnsters, Kristof Van Emelen
  • Patent number: 8334311
    Abstract: Indoline compounds having anti-mitotic activity, useful for the treatment of cancer and other proliferative disorders are provided.
    Type: Grant
    Filed: July 25, 2011
    Date of Patent: December 18, 2012
    Assignee: Joyant Pharmaceuticals, Inc.
    Inventors: Gunnar James Hanson, Qi Wei, Charles Caldwell, Ming Zhou, Lai Wang, Susan Harran
  • Publication number: 20120316334
    Abstract: The present invention relates to Rifaximin polymorphic forms, to their use in medicinal preparations and to therapeutic methods using them.
    Type: Application
    Filed: August 16, 2012
    Publication date: December 13, 2012
    Applicant: SALIX PHARMACEUTICALS, LTD
    Inventors: Karen S. Gushurst, Donglai Yang, Petinka Vlahova, Jeffrey S. Stults
  • Patent number: 8318763
    Abstract: Disclosed are rifamycin derivatives having antibacterial activities, wherein the compounds have the following general formula: wherein: R is hydrogen or acetyl; R1 and R2 are independently selected from the group consisting of hydrogen, (C1-4)alkyl, benzyloxy, mono- and di-(C1-3)alkylamino-(C1-4)alkyl, (C1-3)alkoxy, (C1-4)alkyl, hydroxy-methyl, hydroxy-(C2-4)-alkyl, and nitro or R1 and R2 taken together with two consecutive carbon atoms of the pyridine nucleus form a benzene ring optionally substituted by one or two methyl or ethyl groups and R3 is hydroxyalkyl(C1-4). In addition, processes to obtain these compounds are described.
    Type: Grant
    Filed: May 27, 2009
    Date of Patent: November 27, 2012
    Assignee: Alfa Wassermann S.p.A.
    Inventors: Giuseppe Claudio Viscomi, Manuela Campana, Mahena Folegatti, Paola Righi, Vincenzo Cannata, Goffredo Rosini
  • Patent number: 8318764
    Abstract: The present invention relates to the use of novel macrocyclic compounds of Formula I, wherein the variables Q, Q1, Q2, Q3, and Q4 are defined as described herein, which inhibit JAK and are useful for the treatment of auto-immune and inflammatory diseases.
    Type: Grant
    Filed: September 17, 2010
    Date of Patent: November 27, 2012
    Assignee: Roche Palo Alto LLC
    Inventors: Alam Jahangir, Stephen M Lynch, Michael Soth, Hanbiao Yang
  • Publication number: 20120270841
    Abstract: Diazonamide analogs having anti-mitotic activity, useful for the treatment of cancer and other proliferative disorders, and related pharmaceutical compositions are provided.
    Type: Application
    Filed: April 15, 2012
    Publication date: October 25, 2012
    Inventors: Qi Wei, Ming Zhou, Xiaoming Xu, Charles Caldwell, Susan Harran, Lai Wang
  • Publication number: 20120264763
    Abstract: Indoline compounds having anti-mitotic activity, useful for the treatment of cancer and other proliferative disorders are provided.
    Type: Application
    Filed: July 25, 2011
    Publication date: October 18, 2012
    Inventors: Gunnar James Hanson, Qi Wei, Charles Caldwell, Ming Zhou, Lai Wang, Susan Harran
  • Publication number: 20120264774
    Abstract: Embodiments relate to Rifaximin polymorphic, salt, and hydrate forms, methods of producing polymorphic forms and to their use in medicinal preparations and to therapeutic methods using them.
    Type: Application
    Filed: June 22, 2012
    Publication date: October 18, 2012
    Inventors: Stephan D. Parent, Lisa L. McQueen, Patricia Andres, Paul Schields, Yiduo Wu, Fei Ding, Jared P. Smit
  • Publication number: 20120258166
    Abstract: Forms of rifaximin (INN) antibiotic, such as the poorly crystalline form named rifaximin ? are described, along with the production of medicinal preparations containing rifaximin for oral and topical use.
    Type: Application
    Filed: June 19, 2012
    Publication date: October 11, 2012
    Applicant: ALFA WASSERMANN, S.P.A.
    Inventors: Giuseppe Claudio Viscomi, Manuela Campana, Dario Braga, Donatella Confortini, Vincenzo Cannata, Paolo Righi, Goffredo Rosini
  • Publication number: 20120214989
    Abstract: Crystalline polymorphous forms of rifaximin (INN) antibiotic named rifaximin ? and rifaximin ?, and a poorly crystalline form named rifaximin ?, useful in the production of medicinal preparations containing rifaximin for oral and topical use and obtained by means of a crystallization carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a determinate temperature and for a determinate period of time, followed by a drying carried out under controlled conditions until reaching a settled water content in the end product, are the object of the invention.
    Type: Application
    Filed: May 3, 2012
    Publication date: August 23, 2012
    Applicant: ALFA WASSERMANN, S.P.A.
    Inventors: Giuseppe Claudio Viscomi, Manuela Campana, Dario Braga, Donatella Confortini, Vincenzo Cannata, Paolo Righi, Goffredo Rosini
  • Publication number: 20120207832
    Abstract: Embodiments relate to Rifaximin polymorphic, salt, and hydrate forms, methods of producing polymorphic forms and to their use in medicinal preparations and to therapeutic methods using them.
    Type: Application
    Filed: March 29, 2012
    Publication date: August 16, 2012
    Inventors: Steven D. Parent, Lisa L. McQueen, Patricia Andres, Paul Schields, Yiduo Wu, Fei Ding, Jared P. Smit
  • Publication number: 20120196907
    Abstract: Novel diazonamide analogs having anti-mitotic activity, useful for the treatment of cancer and other proliferative disorders are provided.
    Type: Application
    Filed: March 26, 2012
    Publication date: August 2, 2012
    Inventors: Gunnar James Hanson, Ming Zhou, Qui Wei, Charles Caldwell
  • Publication number: 20120116071
    Abstract: Amorphous rifaximin, methods of making it, and pharmaceutical compositions containing it. Also described are methods of converting amorphous rifaximin to crystalline rifaximin and vice versa.
    Type: Application
    Filed: January 13, 2012
    Publication date: May 10, 2012
    Applicant: CIPLA LIMITED
    Inventors: Dharmaraj Ramachandra RAO, Rajendra Narayanrao KANKAN, Manjinder Singh PHULL, Maruti Ghagare
  • Publication number: 20120108620
    Abstract: The present invention relates to new rifaximin forms kappa, theta, rifaximin:piperazine cocrystal 1 and rifaximin:piperazine cocrystal 2, methods of making same and to their use in medicinal preparations and therapeutic methods.
    Type: Application
    Filed: June 3, 2011
    Publication date: May 3, 2012
    Applicant: SALIX PHARMACEUTICALS, LTD.
    Inventors: Yiduo Wu, Stephan D. Parent, Nathan Carl Schultheiss, Melanie Janelle Bevill, Petinka Vlahova, Travis L. Houston